Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GI 4000

Drug Profile

GI 4000

Alternative Names: GI-4000

Latest Information Update: 13 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlobeImmune
  • Developer GlobeImmune; NantCell; NantKwest
  • Class Cancer vaccines
  • Mechanism of Action Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Breast cancer; Colorectal cancer; Pancreatic cancer
  • Suspended Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 29 Aug 2019 NantKwest withdraws the phase Ib/II QUILT-3.049 trial for Triple negative breast cancer (Second-line therapy or greater, Metastatic disease, Inoperable/Unresectable, Combination therapy) prior to initiation (NCT03175666)
  • 27 Aug 2019 NantKwest withdraws the QUILT-2.024 phase II trial prior to enrolment for Non Small Cell Lung Cancer (Late-stage disease) as the trial was not initiated (NCT03574649)
  • 23 Aug 2019 NantCell withdraws the phase Ib/II QUILT-3.044 trial prior to enrolment for Non-small cell lung cancer (Combination therapy, Second-line therapy or greater) as the trial was not initiated (NCT03169738)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top